
Vaxcyte is looking for a Scientist II, Conjugation Development. The candidate’s primary responsibility will be to lead and execute experimental activities that support company’s pneumococcal conjugate vaccine program with a focus on developing a deeper understanding of the conjugation process. In parallel, the candidate will work on conjugation process development for Vaxcyte’s pipeline programs contributing to process optimization, scalability, and technical readiness for future clinical manufacturing. Specifically, this will include preparation, purification, and analytical characterization of chemically modified polysaccharides and polysaccharide-protein conjugates. The ideal candidate will have significant laboratory experience and an excellent understanding of analytical chemistry principles. The successful candidate will be expected to design, execute, and troubleshoot experiments with minimal guidance. The candidate will also contribute when needed to a range of related areas such as analytical development and stability studies. Responsibilities will additionally include record management, data presentation at group meetings, authorship of laboratory protocols and development reports, communication with external organizations during tech transfer, and actively contributing to collaborative studies with other members of the conjugation group.
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.